

The logo graphic consists of three overlapping, curved, leaf-like shapes in shades of grey, light green, and lime green, positioned above the company name.

ortho·cell

Pioneering Innovative Technologies for Tissue Regeneration

Orthocell Pty Ltd
Building 191 Murdoch University
South Street, Murdoch 6152
Perth, Western Australia

Paul Anderson, CEO
paulanderson@orthocell.com.au
+61 411 861 626

Company Profile




- Soft tissue repair and regeneration company founded in 2006, based on technology developed at UWA
- Cellular therapeutic products and collagen scaffolds:
 - **Regeneration** of damaged tendon and cartilage using the bodies own Tenocyte and Chondrocyte stem cell like cells – Autologous cellular therapeutic
 - **Repair** of biological tissue using proprietary collagen scaffold platform – Medical device
- TGA license to manufacture human tissue granted in Jan 2010
- Revenue generating lead products for tissue regeneration
- Collagen scaffold being prepared for registration in 2012/13
- Experienced team which has developed and sold a cell therapies company to Genzyme

Technology Overview (tendons)

- **Major opportunity** - 34 million Americans – 11% of population
- seek treatment for musculo-skeletal injuries annually
(including tennis elbow and shoulder 'rotator cuff' tendonitis) –
large, dissatisfied market globally
- **Unique** - First in-humans utilizing autologous tendon cells
which are harvested, expanded and implanted for regeneration
- **Proven** - Phase I/IIA trials completed Jan 2010 and double-
blind Phase II trial underway in Holland
- **Commercial progress** - TGA license to manufacture human
tissue enables commercialisation in parallel with evidence base
development
- **Generating early revenues** – more than 50 patients treated
with early adoption by Australian professional sports teams


Tissue Regeneration- cartilage and tendon




Technology Overview (Collagen Scaffold)



- Surgically implanted scaffold repairs soft tissue defects and injuries
- Multiple applications:
 - Orthopaedic: biomechanical support and/or cell delivery, rotator cuff repair – 500,000 surgeries per annum (US/EU)
 - Gynaecological / urological: pelvic floor and bladder wall reconstruction
 - General surgical: Liver resection, hernia repair – 27% of males
 - Pre-clinical evaluation on animal models complete
- Design dossier for ARTG/510(k) registration in final stages of preparation
- Major opportunity: scaffold market synthetic and static
 - little change in 20 years



Product Focus




Celgro™ - Scaffold for tissue regeneration

Surgically implanted scaffold

Multiple applications ENT, Gen Surgical, Orthopaedic, Gynaecological, Dental

Cellular therapeutic - \$AU 500 – 5000




Ortho - ATI™ - Autologous Tenocyte Implantation

Injectable cell suspension

Tendon regeneration

Cellular therapeutic - \$AU 3200



Ortho - ACI™ – Autologous Chondrocyte Implantation

Surgically implanted combined cell / scaffold product

Articular cartilage regeneration

Cellular therapeutic - \$AU 6500



MATT™ - Matrix Augmented Tenocyte Therapy

Surgically implanted combined cell / scaffold product

Tendon regeneration

Cellular therapeutic - \$AU 8500

Board Members



Paul Anderson (Australia) - 15 yrs experience in the medical device and cellular therapeutic fields as former MD of cell therapies company sold to Genzyme in 2005 for \$40M plus milestones.

Matt Callahan (Australia) – Founding CEO of iCeutica Inc which was exited to Iroko Pharma in 2011. Founding CEO Dimerix Bioscience and Partner Stone Ridge Ventures VC Fund.

Lars Lidgren (Sweden) - Over 20 yrs successful start up experience - Chairman of the UN's Bone and Joint Decade. Chairman of the Swedish National Joint Register, Director of the National Board of Health and Welfare, Musculoskeletal Competence Centre, Member of several Editorial Boards.

Fiona Wood (Australia) – Burns surgeon for the last 20 years, Director of the West Australian Burns Unit. Dr Wood was Australian of the Year 2005 and received an Order of Australia Medal (OAM)

Jason Xu (China) - General Manager of manufacturing company D.K.D Group China, Representative of the Peoples Congress of Guangdong Province, vice-president Young Entrepreneurs Assoc.

Highlights



- **Unique tendon repair treatment** – first in-humans globally using revolutionary stem cell technology - addresses large dissatisfied market
- **Collagen scaffold platform technology** – now at registration phase, multiple soft tissue applications – synthetic and static - little innovation for 20 years – strong product pipeline
- **Mature / De risked** – market ready products, pipeline of scaffold products for multiple markets and TGA license paves way for wider commercialisation
- **Clear growth strategy** and multiple exit strategies
- **Experienced management** and scientific advisory team
- **Seeking Expansion Capital**

\$8 million invested in business to date

Thank You.

Cellular Therapeutics and Collagen Scaffolds

Regeneration and repair of tendon and soft tissue defects

Tendon hope in store



TENNIS ELBOW CURED

UWA team fixes tendons with stemcells

A

T LEAST one AFL footballer is among the first athletes in the world to use revolutionary stem-cell technology to treat a damaged tendon.